Argus
•
Sep 02, 2026
CORT: Lowering target price to $119.00
Summary
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: Alnylam Pharmaceuticals, Inc.
Sep 02, 2026
•
ALNY
TGTX: Raising target price to $62.00
Sep 02, 2026
•
TGTX
EXEL: Raising target price to $63.00
Sep 02, 2026
•
EXEL
HALO: Lowering target price to $118.00
Sep 02, 2026
•
HALO
NBIX: Raising target price to $172.00
Sep 02, 2026
•
NBIX
